NYSE American - Delayed Quote USD

Scorpius Holdings, Inc. (SCPX)

Compare
0.3800
-0.0010
(-0.26%)
At close: January 10 at 4:00:00 PM EST
0.3750
-0.00
(-1.32%)
After hours: 7:58:19 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,044.2910
6,994.8380
370.1760
--
2,947.9690
Cost of Revenue
3,824.7090
2,736.9980
81.2950
--
--
Gross Profit
6,219.5820
4,257.8400
288.8810
--
--
Operating Expense
37,529.7920
46,290.0120
40,354.0410
31,170.7010
27,873.3310
Operating Income
-31,310.2100
-42,032.1720
-40,065.1600
-31,170.7010
-24,925.3620
Net Non Operating Interest Income Expense
-908.4170
-319.6490
804.7380
815.3160
566.7180
Other Income Expense
1,224.4560
18.2220
-2,330.5820
-5,191.3960
-2,022.7450
Pretax Income
-30,994.1710
-42,333.5990
-41,591.0040
-35,546.7810
-26,381.3890
Tax Provision
--
-571.1200
-215.9370
-145.9740
--
Net Income Common Stockholders
-28,814.5770
-45,217.1680
-43,434.7060
-35,071.4680
-26,049.7370
Diluted NI Available to Com Stockholders
-28,814.5770
-45,217.1680
-43,434.7060
-35,071.4680
-26,049.7370
Basic EPS
-1.90k
-348.00
-340.00
-282.00
-326.00
Diluted EPS
-1.90k
-348.00
-340.00
-282.00
-326.00
Basic Average Shares
42.1190
130.2320
128.0310
124.5690
79.9120
Diluted Average Shares
42.1190
130.2320
128.0310
124.5690
79.9120
Total Operating Income as Reported
-30,120.2100
-42,032.1720
-40,222.6450
-35,419.0390
-26,124.3620
Total Expenses
41,354.5010
49,027.0100
40,435.3360
31,170.7010
27,873.3310
Net Income from Continuing & Discontinued Operation
-28,814.5770
-45,217.1680
-43,434.7060
-35,071.4680
-26,049.7370
Normalized Income
-30,311.8850
-40,267.8450
-39,109.2771
-30,024.1624
-23,838.5700
Interest Income
66.2120
457.1890
987.2470
815.3160
566.7180
Interest Expense
974.6290
776.8380
182.5090
--
--
Net Interest Income
-908.4170
-319.6490
804.7380
815.3160
566.7180
EBIT
-30,019.5420
-41,556.7610
-41,408.4950
-31,170.7010
-24,925.3620
EBITDA
-22,842.6270
-33,991.2550
-38,262.8550
-30,563.0340
-24,592.2100
Reconciled Cost of Revenue
3,824.7090
2,736.9980
81.2950
--
--
Reconciled Depreciation
7,176.9150
7,565.5060
3,145.6400
607.6670
333.1520
Net Income from Continuing Operation Net Minority Interest
-29,657.2790
-40,146.4610
-40,947.5760
-35,071.4680
-26,049.7370
Total Unusual Items Excluding Goodwill
654.6060
123.0440
-1,847.8930
-5,068.1180
-2,211.1670
Total Unusual Items
654.6060
123.0440
-1,847.8930
-5,068.1180
-2,211.1670
Normalized EBITDA
-23,497.2330
-34,114.2990
-36,414.9620
-25,494.9160
-22,381.0430
Tax Rate for Calcs
--
0.0000
0.0000
0.0000
--
Tax Effect of Unusual Items
--
1.6600
-9.5941
-20.8124
--
12/31/2020 - 7/24/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CYCC Cyclacel Pharmaceuticals, Inc.
0.4199
+1.21%
 
BLRX BioLineRx Ltd.
0.1429
+0.21%
 
MBIO Mustang Bio, Inc.
0.2566
+15.38%
 
ONCO Onconetix, Inc.
0.5100
-6.68%
 
CDT Conduit Pharmaceuticals Inc.
0.1233
+50.37%
 
IMRX Immuneering Corporation
2.0700
+3.50%
 
SPRC SciSparc Ltd.
0.8149
+1.03%
 
SILO Silo Pharma, Inc.
1.7700
+3.51%
 
CNSP CNS Pharmaceuticals, Inc.
0.1178
+1.55%
 
NLSP NLS Pharmaceutics AG
2.3200
-3.73%